Plant Name: Chelidonium majus
Taxonomic Information:
Plant ID: NPO11457
Plant Latin Name: Chelidonium majus
Taxonomy Genus: Chelidonium
Taxonomy Family: Papaveraceae
Plant External Links:
NCBI TaxonomyDB:
71251
Plant-of-the-World-Online:
n.a.
Used in Medicines:
Country/Region:
Turkey; Albania; Italy; Portugal; Lithuania; Sweden; China; South Korea; Russia; Spain; BulgariaTraditional Medicine System:
TCMMedicinal Functions:
Acrid; Alterative; Anodyne; Antispasmodic; Cancer; Cholagogue; Diaphoretic; Diuretic; Hydrogogue; Narcotic; Ophthalmic; Purgative; Stomachic; Warts
Geographical Distribution:
Turkey; Albania; Italy; Portugal; Lithuania; Sweden; China; South Korea; Russia; Spain; Bulgaria
Example Image
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| HRH3; HRH1; HRH4; TAAR1; DRD2; DRD1; | |
| TSHR; | |
| ACHE; | |
| CA2; CA7; CA4; CA12; | |
| HSD17B10; | |
| MMP2; MMP9; MMP1; | |
| NFKB1; | |
| F3; THPO; LMNA; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: | CYP2D6; |
|---|
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
| Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
| Metallo protease | MMP1 | Matrix metalloproteinase-1 | P03956 | CHEMBL332 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Small molecule receptor (family A GPCR) | HRH3 | Histamine H3 receptor | Q9Y5N1 | CHEMBL264 |
| Small molecule receptor (family A GPCR) | HRH1 | Histamine H1 receptor | P35367 | CHEMBL231 |
| Small molecule receptor (family A GPCR) | HRH4 | Histamine H4 receptor | Q9H3N8 | CHEMBL3759 |
| Small molecule receptor (family A GPCR) | TAAR1 | Trace amine-associated receptor 1 | Q96RJ0 | CHEMBL5857 |
| Small molecule receptor (family A GPCR) | DRD2 | Dopamine D2 receptor | P14416 | CHEMBL217 |
| Small molecule receptor (family A GPCR) | DRD1 | Dopamine D1 receptor | P21728 | CHEMBL2056 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Unclassified | F3 | Coagulation factor III | P13726 | CHEMBL4081 |
| Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.398E-09 | 3.044E-05 | CA12, CA2, CA4, CA7 |
| MF | GO:0060089; molecular transducer activity | GO:0004969; histamine receptor activity | 2.210E-08 | 1.604E-04 | HRH1, HRH3, HRH4 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 5.944E-08 | 2.589E-04 | CA12, CA2, CA4, CA7 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 1.362E-07 | 3.339E-04 | CA12, CA2, CA4, CA7 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 3.375E-06 | 3.675E-03 | CA2, CA7 |
| BP | GO:0065007; biological regulation | GO:0007194; negative regulation of adenylate cyclase activity | 5.383E-06 | 4.884E-03 | DRD2, HRH3, HRH4 |
| BP | Unclassified; | GO:0021853; cerebral cortex GABAergic interneuron migration | 1.124E-05 | 7.414E-03 | DRD1, DRD2 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 1.580E-05 | 9.403E-03 | CA12, CA2, CA4, CA7, MMP1, MMP2, MMP9 |
| BP | GO:0007610; behavior | GO:0008542; visual learning | 1.856E-05 | 9.858E-03 | DRD1, DRD2, HRH1 |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09130 Environmental Information Processing | 09133 Signaling molecules and interaction | hsa04080 | Neuroactive ligand-receptor interaction | 8.927E-09 | 4.151E-07 | HRH1, HRH3, HRH4, DRD1, DRD2, TAAR1, TSHR |
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 2.118E-09 | 1.970E-07 | CA12, CA2, CA4, CA7 |
| 09160 Human Diseases | 09161 Cancers | hsa05219 | Bladder cancer | 1.037E-05 | 3.213E-04 | MMP1, MMP2, MMP9 |
| 09160 Human Diseases | 09164 Substance dependence | hsa05030 | Cocaine addiction | 1.782E-05 | 4.143E-04 | DRD1, DRD2, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04024 | cAMP signaling pathway | 4.985E-05 | 9.271E-04 | DRD1, DRD2, NFKB1, TSHR |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 1.556E-04 | 2.412E-03 | MMP2, F3, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 7.002E-04 | 8.140E-03 | MMP1, MMP2, MMP9, NFKB1 |
| 09150 Organismal Systems | 09155 Excretory system | hsa04964 | Proximal tubule bicarbonate reclamation | 2.622E-04 | 3.483E-03 | CA2, CA4 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| H00-H59: Diseases of the eye and adnexa | Ocular allergy | H00-H59 | HRH1; |
| NA: NA | Urticaria | NA | HRH1; |
| NA: NA | Vomiting | NA | DRD2; HRH1; |
| H60-H95: Diseases of the ear and mastoid process | Vertigo meniere's disease | H81, H81.0, R42 | HRH1; |
| NA: NA | Malignant essential hypertension | NA | DRD2; |
| NA: NA | Meniere's disease | NA | HRH1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | HRH1; |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | CYP2D6; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Excessive daytime sleepiness | F51.1, G47.1 | HRH3; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | DRD2; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Mild to moderate alzheimer disease | G30 | HRH3; |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6; |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine headaches | G43 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR; |
| NA: NA | Vertigo's disease | NA | HRH1; |
| NA: NA | False perceptions | NA | DRD2; |
| O00-O9A: Pregnancy, childbirth and the puerperium | Postpartum haemorrhage | O72 | DRD2; |
| I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Anesthesia | R20.0 | HRH1; |
| C00-D49: Neoplasms | Ovarian cancer | C56 | MMP2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | HRH3; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Musculoskeletal pain | R52, G89 | HRH3; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | MMP9; |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Idiopathic thrombocytopenic purpura | D69.3 | DRD2; |
| NA: NA | Corneal vascularity | NA | DRD2; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | MMP2; F3; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; DRD1; DRD2; HRH1; |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
| NA: NA | Morning sickness | NA | HRH1; |
| H00-H59: Diseases of the eye and adnexa | Ophthalmic disease | H00-H59 | DRD2; |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; ACHE; CA2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Substance dependence | F10-F19 | DRD1; DRD2; |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR; |
| J00-J99: Diseases of the respiratory system | Adult respiratory distress syndrome | J80 | F3; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | HRH3; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | MMP2; |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | HRH1; HRH3; HRH4; |
| NA: NA | Allergic disorders | NA | HRH1; |
| C00-D49: Neoplasms | Allergic conjunctivitis | C91.0, H10, H10.45, T78.4 | HRH1; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; DRD2; HRH3; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | DRD2; HRH1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Allergic skin disorders | L00-L99 | HRH1; |
| NA: NA | Malignant phaeochromocytoma | NA | DRD2; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Dry cough | R05 | HRH1; |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR; |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | HRH3; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | MMP1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | DRD2; HRH3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Advanced stage Parkinson's disease | F02.3, G20 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sexual dysfunction | F52 | DRD2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | MMP1; |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | MMP2; |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | DRD2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obese insulin-resistant disorders | E11 | HRH3; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | HRH1; HRH3; |
| I00-I99: Diseases of the circulatory system | Angina pectoris | I20 | DRD2; |
| K00-K95: Diseases of the digestive system | Dermal necrosis | K05 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Dementia | F01-F07 | DRD1; HRH3; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | MMP9; MMP2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Acromegaly | E22.0 | DRD2; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | MMP2; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Depressive fatigue | R53.82 | DRD2; |
| I00-I99: Diseases of the circulatory system | Hypotension | I95 | DRD2; |
| NA: NA | Coughs | NA | HRH1; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cough | R05 | HRH1; |
| G00-G99: Diseases of the nervous system G00-G99 | Narcolepsy | G47.4 | HRH3; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Nausea | R11 | DRD2; HRH1; |
| J00-J99: Diseases of the respiratory system | Nasal congestion | J34.89 | DRD2; HRH1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sleep disorders | F51, G47 | HRH1; HRH3; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Carcinoid syndrome | E34.0 | DRD2; |
| C00-D49: Neoplasms | Cancer | C00-C96 | NFKB1; ACHE; HRH1; MMP9; MMP2; |
| J00-J99: Diseases of the respiratory system | Bronchitis | J20-J21, J42 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | HRH3; |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | DRD2; |
| K00-K95: Diseases of the digestive system | Gastrointestinal problems | K30-K31, Q40-Q41 | DRD2; |
| O00-O9A: Pregnancy, childbirth and the puerperium | Excessive bleeding following childbirth and spontaneous or elective abortion | O04 | DRD1; |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
| NA: NA | Upper abdominal bloating | NA | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ACHE; DRD1; DRD2; HRH1; HRH3; |
| I00-I99: Diseases of the circulatory system | Cardiac failure | I50 | DRD2; |
| I00-I99: Diseases of the circulatory system | Cardiotonic | I50 | DRD2; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | DRD2; HRH1; HRH4; |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; |
| J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | HRH1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | MMP1; HRH4; |
| NA: NA | Schizoaffective disorders | NA | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Bipolar disorder | F31, F40-F42 | DRD2; |
| NA: NA | Benign prostatic hypertrophy | NA | DRD2; |
| I00-I99: Diseases of the circulatory system | Bleeding | I74, I80-I82 | F3; |
| J00-J99: Diseases of the respiratory system | Hay fever | J30 | HRH1; |
| NA: NA | Edema | NA | CA2; |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Emesis | R11 | DRD2; |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
| NA: NA | Respiratory allergies | NA | HRH1; |
| J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | HRH1; |
| C00-D49: Neoplasms | Breast cancer | C50 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | DRD1; DRD2; HRH3; |
| J00-J99: Diseases of the respiratory system | Seasonal and perennial allergic rhinitis and vasomotor rhinitis | J30 | HRH1; |
| NA: NA | Perennial and seasonal allergic rhinitis | NA | HRH1; |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Eating disorder | E66, F50, I10-I16, I50 | HRH3; |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
| I00-I99: Diseases of the circulatory system | Pulmonary hypertension | I27.0, I27.2 | DRD2; |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychiatric disorder | F01-F99 | DRD1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychosis | F20-F29 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | DRD1; DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; DRD1; HRH3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cocaine addiction | F14.2 | DRD1; |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | HRH1; |
| I00-I99: Diseases of the circulatory system | Maintain blood pressure in hypotensive states | I10 | DRD2; |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | DRD2; |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | HRH3; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; DRD2; |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Huntington's disease | F02.2, G10 | DRD2; |
| NA: NA | Hyperaemia | NA | DRD2; |
| NA: NA | Itching | NA | DRD2; HRH1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1; DRD1; |
| NA: NA | Peripheral vasoconstriction | NA | DRD2; |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | HRH3; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperprolactinemia | E22.1 | DRD2; |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | DRD1; DRD2; |
| NA: NA | Hypersensitivity reactions | NA | HRH1; |
| NA: NA | Common cold | NA | HRH1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CYP2D6; CA2; DRD2; HRH1; |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | DRD2; |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | DRD2; HRH4; |
| NA: NA | Inflammatory diseases | NA | DRD2; |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; DRD2; HRH1; HRH3; |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2; |
| NA: NA | Vasomotor rhinitis | NA | HRH1; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
